Pilot Test of Bioaugmentation for Treatment of 1,4-Dioxane in Mixed Contaminant Source Zone
Abstract
1,4-Dioxane is widely associated with chlorinated solvent source-zones/plumes and presents a significant remediation challenge due to its high mobility and persistence. Geochemical conditions that are suitable for chlorinated solvent degradation (e.g., strongly reducing conditions) are generally incompatible with 1,4-dioxane degradation. Direct metabolism of 1,4-dioxane may be feasible under aerobic conditions but requires specific bacteria that are often not naturally occurring.
This presentation will focus on an industrial site in the southeast United States. The source area is impacted with mixed constituents including chlorinated solvents, hydrocarbons, and 1,4-dioxane. Under ambient conditions there is a robust microbial community with both aerobic and anaerobic biomarkers. While natural attenuation appears to be occurring, engineered methods are being evaluated to expedite treatment.
An aerobic bioremediation pilot test was started in the summer of 2022 to investigate direct metabolism with use of a biosparge system and delivery of SiREM’s DXO-88TM bioaugmentation culture. Performance assessment included groundwater sampling for VOCs, 1,4-dioxane, geochemical parameters, and microbial community evaluation (qPCR and NextGen sequencing). Data collection to date indicates that the conditions amenable to degradation of 1,4-dioxane are becoming established. Data available through fall 2023 indicates 1,4-dioxane concentration reductions of 50% to 90% have been attained after 16 months of system operation. The results suggest that bioaugmentation is a feasible remedy for 1,4-dioxane source areas.
SiREM supports field application of bioaugmentation cultures like the described pilot test above. Effective implementation of bioaugmentation cultures at complex sites are additionally supported by bench scale treatability studies and molecular genetic testing. Treatability studies can be used to evaluate bioaugmentation cultures as well as other remedial technologies with samples from the Site to provide insight into field performance. Sandra’s presentation will provide additional information on the DXO-88TM bioaugmentation culture, the molecular targets of interest, and highlight where treatability studies provide value for 1,4-dioxane remedies.
The Presenters




